Bruce E. Sands
Icahn School of Medicine at Mount Sinai
Internal medicineSurgeryIntensive care medicineAdverse effectImmunologyPlaceboColitisVedolizumabInfliximabInflammatory bowel diseaseMaintenance therapyTofacitinibUstekinumabDiseaseCrohn's diseaseUlcerative colitisIn patientClinical trialMedicineGastroenterology
Publications 669
#1Robert Hirten (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 12
#2Matteo Danieletto (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 10
Last. Renata Pyzik (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 8
view all 20 authors...
BACKGROUND: The Coronavirus Disease 2019 (COVID-19) pandemic has resulted in a high degree of psychological distress in health care workers (HCWs). There is a need to characterize which HCWs are at an increased risk of developing psychological effects from the pandemic. Given differences in the response of individuals to stress, evaluation of both the perceived and physiological consequence of stressors provides a comprehensive evaluation of its impact. OBJECTIVE: In the current study the object...
#1Bruce E. SandsH-Index: 94
#2Peter M. IrvingH-Index: 54
Last. Stephen B. HanauerH-Index: 125
view all 19 authors...
#1Severine Vermeire (Katholieke Universiteit Leuven)H-Index: 146
#2Michael V. Chiorean (Virginia Mason Medical Center)H-Index: 11
Last. William J. Sandborn (UCSD: University of California, San Diego)H-Index: 182
view all 11 authors...
Background and aims Etrasimod is an oral, selective, sphingosine 1-phosphate receptor modulator. In a phase 2, randomised, double-blind, placebo-controlled trial in adults with moderately-to-severely active ulcerative colitis (OASIS), etrasimod 2 mg provided significant benefit versus placebo and was generally well tolerated. This open-label extension (OLE) evaluated safety and efficacy of etrasimod for up to 52 weeks. Methods In OASIS, 156 patients received etrasimod 1 mg, etrasimod 2 mg, or pl...
#1Sazonovs A (Wellcome Trust Sanger Institute)
#1Aleksejs Sazonovs (Wellcome Trust Sanger Institute)H-Index: 6
Last. Baras A
view all 128 authors...
Genome-wide association studies (GWAS) have identified hundreds of loci associated with Crohns disease (CD); however, as with all complex diseases, deriving pathogenic mechanisms from these non-coding GWAS discoveries has been challenging. To complement GWAS and better define actionable biological targets, we analysed sequence data from more than 30,000 CD cases and 80,000 population controls. We observe rare coding variants in established CD susceptibility genes as well as ten genes where codin...
#1William J. Sandborn (UCSD: University of California, San Diego)H-Index: 182
#2Brian G. Feagan (UWO: University of Western Ontario)H-Index: 115
Last. Subrata Ghosh (University of Birmingham)H-Index: 85
view all 13 authors...
Background Ustekinumab is currently approved globally in Crohn's disease (CD) and psoriatic diseases. Recent phase 3 data demonstrate safety/efficacy in ulcerative colitis (UC). Crohn's disease and UC phase 3 programs had similar study designs, facilitating integrated safety analyses. Methods Data from 6 ustekinumab phase 2/3 CD and UC studies were pooled, and safety was evaluated through 1 year. Patients received 1 placebo or ustekinumab (generally 130 mg or ~6 mg/kg) intravenous induction, the...
12 CitationsSource
#1Laurent Peyrin-Biroulet (French Institute of Health and Medical Research)H-Index: 103
#2Edward V. Loftus (Mayo Clinic)H-Index: 114
Last. Richard A. LirioH-Index: 7
view all 10 authors...
BACKGROUND AND AIMS VARSITY showed superior clinical remission and endoscopic improvement in ulcerative colitis with vedolizumab versus adalimumab. This analysis compared histologic outcomes. METHODS Patients in VARSITY were randomized 1:1 to vedolizumab 300-mg intravenous infusions or adalimumab 40-mg subcutaneous injections. Geboes and Robarts Histopathology Index (RHI) scores were used to assess prespecified histologic exploratory endpoints (histologic remission [Geboes <2 or RHI ≤2] and mini...
GOAL The goal of this study was to describe medication utilization patterns in older inflammatory bowel disease (IBD) patients. BACKGROUND Despite a growing population of older patients with Crohn's disease (CD) and ulcerative colitis (UC), questions remain regarding medication utilization patterns in comparison to younger populations. MATERIALS AND METHODS We collected data from the 34 sites in TARGET-IBD, a multicenter, observational cohort. The primary outcome in this study was the IBD-specif...
#1Robert Hirten (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 12
#2Stephanie Stanley (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 2
Last. Bruce E. Sands (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 94
view all 12 authors...
BACKGROUND Wearable devices are designed to capture health-related and physiological data. They may be able to improve inflammatory bowel disease management and address evolving research needs. Little is known about patient perceptions for their use in the study and management of inflammatory bowel disease. AIMS The aim of this survey study is to understand patient preferences and interest in wearable technology. METHODS Consecutive adult patients who self-reported having inflammatory bowel dise...
3 CitationsSource
#1Christopher Ma (U of C: University of Calgary)H-Index: 21
#2Rocio Sedano (UWO: University of Western Ontario)H-Index: 3
Last. Vipul Jairath (UWO: University of Western Ontario)H-Index: 20
view all 25 authors...
ABSTRACT Background & Aims Histopathology is an emerging treatment target in ulcerative colitis (UC) clinical trials. We aim to provide guidance on standardizing biopsy collection protocols, identifying optimal evaluative indices, and defining thresholds for histologic response and remission after treatment. Methods An international, interdisciplinary expert panel of 19 gastroenterologists and gastrointestinal pathologists was assembled. A modified RAND/University of California Los Angeles appro...
3 CitationsSource